|
| Press Releases |
|
 |
|
| Wednesday, May 8, 2024 |
|
|
NEC X Invests in Public Safety Startup Multitude Insights, Scaling AI-Powered Collaboration and Information Sharing for Law Enforcement |
| NEC X, the Silicon Valley-based innovation accelerator and venture studio backed by global IT leader NEC, today announced a new investment in Multitude Insights, the provider of a transformative AI-powered solution enabling greater collaboration and faster case resolution for law enforcement agencies and first responders. more info >> |
|
| Wednesday, April 24, 2024 |
|
|
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance |
| NEC Corporation has expanded its "NEC cotomi" generative AI services with the development of "NEC cotomi Pro" and "NEC cotomi Light," two new high-speed generative AI Large Language Models (LLM) featuring updated training data and architectures. more info >> |
|
| Monday, April 22, 2024 |
|
|
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II |
| NEC Corporation (NEC; TSE: 6701) today announced a strategic investment in "Seraphim Space Venture Fund II," a pioneering venture capital fund specializing in the space industry and operated by Seraphim Space, the most prolific investor globally in this domain. more info >> |
|
| Tuesday, April 16, 2024 |
|
|
NEC、SBTiからNet-Zero目標の認定を取得 |
| NECは、SBTi(The Science Based Targets initiative、注1)からNet-Zero目標の認定を取得しました。 more info >> |
|
| Thursday, April 11, 2024 |
|
|
DOCOMO, NTT, NEC and Fujitsu Develop Top-level Sub-terahertz 6G Device Capable of Ultra-high-speed 100 Gbps Transmission |
| NTT DOCOMO, INC., NTT Corporation, NEC Corporation and Fujitsu Limited jointly announced today the development of a top-level (1) wireless device capable of ultra-high-speed 100 Gbps transmissions in the 100 GHz and 300 GHz sub-terahertz bands. more info >> |
|
| Wednesday, April 10, 2024 |
|
|
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024 |
| Transgene, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and NEC Corporation, a leader in IT, network and AI technologies, announced that new data will be presented on TG4050, an individualized neoantigen cancer vaccine, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA. more info >> |
|
| Monday, April 8, 2024 |
|
|
NEC white paper proposes comprehensive process workflow for the application of AI-driven personalized cancer vaccines |
| NEC Corporation (TSE: 6701) has released a white paper, "Towards the realization of AI drug development: Comprehensive process workflow for the commercial use of personalized cancer vaccines". more info >> |
|
| Monday, March 25, 2024 |
|
|
NEC develops marketing strategy planning & effectiveness simulation technology using generative AI |
| NEC Corporation (TSE: 6701) has developed a marketing strategy planning & effectiveness simulation technology that utilizes generative AI to identify latent needs of customers and generate optimal measures. more info >> |
|
| Friday, March 22, 2024 |
|
|
NEC and NTT successfully conduct first-of-its-kind long-distance transmission experiment over 7,000km using 12-core optical fiber |
| NEC Corporation (TSE: 6701) and NTT Corporation (NTT) today announced that they have successfully conducted a first-of-its-kind transoceanic-class 7,280km transmission experiment using a coupled 12-core multicore fiber(1), which consists of 12 optical signal transmission paths in a standard outer diameter optical fiber (0.125 mm). more info >> |
|
| Thursday, March 21, 2024 |
|
|
NEC and Tokyo Medical and Dental University use AI to assist self-care for chronic lower back pain |
| NEC Corporation (TSE: 6701) and Tokyo Medical and Dental University (TMDU) have developed a technology to support self-care for chronic non-specific lower back pain (CLBP) by using artificial intelligence (AI) to analyze image and interview data taken with smart devices. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
維昇藥業（2561.HK）維臻高(R)獲批：重長效生長激素王者登場 重構百億市場的商業天花板
Feb 25, 2026 13:11 HKT/SGT
|
|
|
CanSinoBIO's Menhycia (R) Secures Expanded Age Indication, Unlock Broader Long-Term Growth Potential
Feb 25, 2026 12:46 HKT/SGT
|
|
|
ベイシアのスーパーマーケット内の冷蔵・冷凍庫の温度点検・記録業務を富士通のIoT可視化ソリューションにより自動化
Feb 25, 2026 12:00: JST
|
|
|
Beisia Automates Supermarket Refrigerator Temperature Monitoring and Recording with Fujitsu's IoT Visualization Solution
Feb 25, 2026 11:00 HKT/SGT
|
|
|
國泰君安國際獲批使用SIMM 衍生品風險管理接軌國際標準
Feb 25, 2026 10:34 HKT/SGT
|
|
|
国泰君安国际获批使用SIMM 衍生品风险管理接轨国际标准
Feb 25, 2026 10:34 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 22:30: JST
|
|
|
CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China
Feb 24, 2026 21:30 HKT/SGT
|
|
|
TANAKA to Provide Medals for the Tokyo Marathon 2026 That Represent All the Participants in the Event with Woven Lines
Feb 24, 2026 22:00 JST
|
|
|
康哲藥業（867.HK/8A8.SG）：創新藥磷酸蘆可替尼乳膏增加特應性皮炎（AD）適應症中國上市許可申請獲受理並獲納入優先審評
Feb 24, 2026 20:31 HKT/SGT
|
|
|
康哲药业（867.HK/8A8.SG）：创新药磷酸芦可替尼乳膏增加特应性皮炎（AD）适应症中国上市许可申请获受理并获纳入优先审评
Feb 24, 2026 20:19 HKT/SGT
|
|
|
Mitsubishi Shipbuilding Ships First Units of Systems for Marine Ammonia-Fueled Engines
Feb 24, 2026 20:07 JST
|
|
|
MHI Unveils "DIAVAULT," a Secure, High Performance Edge Data Center Platform
Feb 24, 2026 19:55 JST
|
|
|
康希諾生物曼海欣(R)擴齡正式獲批 為公司長期價值開啟更廣闊發展空間
Feb 24, 2026 18:15 HKT/SGT
|
|
|
康希诺生物曼海欣(R)扩龄正式获批 为公司长期价值开启更广阔发展空间
Feb 24, 2026 18:08 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
